BACKGROUND:Deep brain stimulation provides significant symptomatic benefit for people with advanced Parkinson's disease whose symptoms are no longer adequately controlled with medication. Preliminary evidence suggests that subthalamic nucleus stimulation may also be efficacious in early Parkinson's disease, and results of animal studies suggest that it may spare dopaminergic neurons in the substantia nigra. OBJECTIVE: We report the methodology and design of a novel Phase I clinical trial testing the safety and tolerability of deep brain stimulation in early Parkinson's disease and discuss previous failed attempts at neuroprotection. METHODS: We recently conducted a prospective, randomized, parallel-group, single-blind pilot clinical trial of deep brain stimulation in early Parkinson's disease. Subjects were randomized to receive either optimal drug therapy or deep brain stimulation plus optimal drug therapy. Follow-up visits occurred every six months for a period of two years and included week-long therapy washouts. RESULTS:Thirty subjects with Hoehn &; Yahr Stage II idiopathic Parkinson's disease were enrolled over a period of 32 months. Twenty-nine subjects completed all follow-up visits; one patient in the optimal drug therapy group withdrew from the study after baseline. Baseline characteristics for all thirty patients were not significantly different. CONCLUSIONS: This study demonstrates that it is possible to recruit and retain subjects in a clinical trial testing deep brain stimulation in early Parkinson's disease. The results of this trial will be used to support the design of a Phase III, multicenter trial investigating the efficacy of deep brain stimulation in early Parkinson's disease.
RCT Entities:
BACKGROUND: Deep brain stimulation provides significant symptomatic benefit for people with advanced Parkinson's disease whose symptoms are no longer adequately controlled with medication. Preliminary evidence suggests that subthalamic nucleus stimulation may also be efficacious in early Parkinson's disease, and results of animal studies suggest that it may spare dopaminergic neurons in the substantia nigra. OBJECTIVE: We report the methodology and design of a novel Phase I clinical trial testing the safety and tolerability of deep brain stimulation in early Parkinson's disease and discuss previous failed attempts at neuroprotection. METHODS: We recently conducted a prospective, randomized, parallel-group, single-blind pilot clinical trial of deep brain stimulation in early Parkinson's disease. Subjects were randomized to receive either optimal drug therapy or deep brain stimulation plus optimal drug therapy. Follow-up visits occurred every six months for a period of two years and included week-long therapy washouts. RESULTS: Thirty subjects with Hoehn & Yahr Stage II idiopathic Parkinson's disease were enrolled over a period of 32 months. Twenty-nine subjects completed all follow-up visits; one patient in the optimal drug therapy group withdrew from the study after baseline. Baseline characteristics for all thirty patients were not significantly different. CONCLUSIONS: This study demonstrates that it is possible to recruit and retain subjects in a clinical trial testing deep brain stimulation in early Parkinson's disease. The results of this trial will be used to support the design of a Phase III, multicenter trial investigating the efficacy of deep brain stimulation in early Parkinson's disease.
Authors: Michael S Remple; Courtney H Bradenham; C Chris Kao; P David Charles; Joseph S Neimat; Peter E Konrad Journal: Mov Disord Date: 2011-05-03 Impact factor: 10.338
Authors: C Warren Olanow; Olivier Rascol; Robert Hauser; Paul D Feigin; Joseph Jankovic; Anthony Lang; William Langston; Eldad Melamed; Werner Poewe; Fabrizio Stocchi; Eduardo Tolosa Journal: N Engl J Med Date: 2009-09-24 Impact factor: 91.245
Authors: Frances M Weaver; Kenneth Follett; Matthew Stern; Kwan Hur; Crystal Harris; William J Marks; Johannes Rothlind; Oren Sagher; Domenic Reda; Claudia S Moy; Rajesh Pahwa; Kim Burchiel; Penelope Hogarth; Eugene C Lai; John E Duda; Kathryn Holloway; Ali Samii; Stacy Horn; Jeff Bronstein; Gatana Stoner; Jill Heemskerk; Grant D Huang Journal: JAMA Date: 2009-01-07 Impact factor: 56.272
Authors: David Charles; Peter E Konrad; Joseph S Neimat; Anna L Molinari; Michael G Tramontana; Stuart G Finder; Chandler E Gill; Mark J Bliton; Chris Kao; Fenna T Phibbs; Peter Hedera; Ronald M Salomon; Kevin R Cannard; Lily Wang; Yanna Song; Thomas L Davis Journal: Parkinsonism Relat Disord Date: 2014-03-28 Impact factor: 4.891
Authors: Mallory L Hacker; Maxim Turchan; Lauren E Heusinkveld; Amanda D Currie; Sarah H Millan; Anna L Molinari; Peter E Konrad; Thomas L Davis; Fenna T Phibbs; Peter Hedera; Kevin R Cannard; Li Wang; David Charles Journal: Neurology Date: 2020-06-29 Impact factor: 11.800
Authors: Mallory L Hacker; Amanda D Currie; Anna L Molinari; Maxim Turchan; Sarah M Millan; Lauren E Heusinkveld; Jonathon Roach; Peter E Konrad; Thomas L Davis; Joseph S Neimat; Fenna T Phibbs; Peter Hedera; Daniel W Byrne; David Charles Journal: J Parkinsons Dis Date: 2016 Impact factor: 5.568
Authors: Mallory L Hacker; Mahlon R DeLong; Maxim Turchan; Lauren E Heusinkveld; Jill L Ostrem; Anna L Molinari; Amanda D Currie; Peter E Konrad; Thomas L Davis; Fenna T Phibbs; Peter Hedera; Kevin R Cannard; Lea T Drye; Alice L Sternberg; David M Shade; James Tonascia; David Charles Journal: Neurology Date: 2018-06-29 Impact factor: 11.800